Sarepta was Arrowhead Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $696.80M of $829.45M (84%).
| Customer | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Sarepta | — | — | — | $696.80M | |
| Sanofi | — | — | — | $130.00M | |
| Takeda | $85.83M | $162.52M | $866.00K | — | |
| Gsk | $124.76M | $29.66M | $2.69M | $2.65M | |
| Amgen | — | $25.00M | — | — | |
| Horizon | $29.18M | $23.21M | — | — | |
| Janssen | $3.45M | $356.00K | — | — | |
| Total | $243.23M | $240.74M | $3.55M | $829.45M |
Arrowhead Pharmaceuticals brought in $829.45M from its three revenue lines in fiscal 2025, the year ended September 30, 2025. Arrowhead Pharmaceuticals regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $3.55M. Sarepta was the largest at $696.80M (84.0%), ahead of Sanofi at $130.00M (15.7%) and Gsk at $2.65M (0.3%).
Arrowhead Pharmaceuticals began breaking out Sarepta in fiscal 2025 and Sanofi in fiscal 2025. Arrowhead Pharmaceuticals stopped reporting Amgen ($25.00M in fiscal 2023), Horizon ($23.21M in fiscal 2023), Takeda ($866.00K in fiscal 2024) and one other as separate revenue lines.
Sarepta was Arrowhead Pharmaceuticals’s largest revenue line in fiscal 2025, bringing in $696.80M of $826.80M (84%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2025 |
|---|---|
| Sarepta | $696.80M |
| Sanofi | $130.00M |
| Total | $826.80M |
Arrowhead Pharmaceuticals brought in $826.80M from its two revenue lines in fiscal 2025, the year ended September 30, 2025. Sarepta was the largest at $696.80M (84.3%), ahead of Sanofi at $130.00M (15.7%).
Janssen was Arrowhead Pharmaceuticals’s largest revenue line in fiscal 2020, bringing in $65.00M of $85.10M (76%).
| Type Of Arrangement | FY 2017 | FY 2018 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|---|
| Janssen | — | — | — | $167.50M | $65.00M |
| Amgen | $31.30M | $16.10M | — | $300.00K | $20.10M |
| Amgen Incorporated | — | — | $16.10M | — | — |
| Total | $31.30M | $16.10M | $16.10M | $167.80M | $85.10M |
Arrowhead Pharmaceuticals brought in $85.10M from its two revenue lines in fiscal 2020, the year ended September 30, 2020. That was down 49.3% from $167.80M in fiscal 2019. Janssen was the largest at $65.00M (76.4%), ahead of Amgen at $20.10M (23.6%).
Compared with fiscal 2019, Amgen grew 6,600.0% to $20.10M, while Janssen fell 61.2% to $65.00M.
Arrowhead Pharmaceuticals began breaking out Janssen in fiscal 2019, when it brought in $167.50M. Arrowhead Pharmaceuticals stopped reporting Amgen Incorporated as a separate revenue line after fiscal 2018, when it brought in $16.10M.
Arrowhead Pharmaceuticals (ARWR) reports its revenue by customer, by collaborative arrangement and arrangement other than collaborative and by type of arrangement. In fiscal 2025, Sarepta was its largest revenue line, bringing in $696.80M (84.0% of the total), followed by Sanofi at $130.00M (15.7%).
Sarepta was Arrowhead Pharmaceuticals' largest revenue line in fiscal 2025, bringing in $696.80M, or 84.0% of the $829.45M total across its three revenue lines.
Amgen grew faster than Janssen in fiscal 2020, up 6,600.0% from $300.00K to $20.10M. Janssen fell 61.2% to $65.00M.
Every figure comes from Arrowhead Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Arrowhead Pharmaceuticals gives it, and years follow its fiscal calendar.
Arrowhead Pharmaceuticals' revenue by customer goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.